C4 Therapeutics IncNASDAQ:CCCC
- LAST PRICE4.6400
- TODAY'S CHANGE (%)-0.0700 (-1.4862%)
- Bid / Lots4.6400/ 2
- Ask / Lots4.6600/ 5
- Open / Previous Close4.6500 / 4.7100
- Day Range
- 52 Week Range
- Volume202,191
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CCCC |
|---|---|---|
| 09:32 ET | 15466 | 4.76 |
| 09:34 ET | 4970 | 4.75 |
| 09:36 ET | 2375 | 4.75 |
| 09:38 ET | 2680 | 4.75 |
| 09:39 ET | 1533 | 4.75 |
| 09:41 ET | 6035 | 4.76 |
| 09:43 ET | 3451 | 4.75 |
| 09:45 ET | 2827 | 4.745 |
| 09:48 ET | 1105 | 4.745 |
| 09:50 ET | 4170 | 4.765 |
| 09:52 ET | 3477 | 4.7416 |
| 09:54 ET | 1546 | 4.75 |
| 09:56 ET | 1697 | 4.76 |
| 09:57 ET | 716 | 4.75 |
| 09:59 ET | 2413 | 4.755 |
| 10:01 ET | 13910 | 4.84 |
| 10:03 ET | 10711 | 4.868 |
| 10:06 ET | 9717 | 4.84 |
| 10:08 ET | 2255 | 4.8 |
| 10:10 ET | 5785 | 4.79 |
| 10:12 ET | 5054 | 4.77 |
| 10:14 ET | 1925 | 4.76 |
| 10:15 ET | 6649 | 4.745 |
| 10:17 ET | 4464 | 4.745 |
| 10:19 ET | 31112 | 4.66 |
| 10:21 ET | 15870 | 4.665 |
| 10:24 ET | 6193 | 4.64 |
Jun 10, 2024
Press Release: C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors, from 7:00AM ET on Monday Jun 10, 2024 by Dow Jones
7:00AM ET on Monday Jun 10, 2024 by Dow JonesC4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors, from 7:00AM ET on Monday Jun 10, 2024 by Dow Jones
7:00AM ET on Monday Jun 10, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
C4 Therapeutics Inc | 324.1M | -2.0x | --- |
TScan Therapeutics Inc | 327.2M | -4.9x | --- |
Molecular Partners AG | 287.0M | -3.6x | --- |
MeiraGTx Holdings PLC | 270.7M | -3.2x | --- |
Absci Corp | 332.5M | -2.5x | --- |
Ocugen Inc | 303.7M | -5.3x | --- |
Company Information
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on advancing targeted protein degradation science to create a new generation of small-molecule medicines that transform patients’ lives. By leveraging its proprietary Target ORiented ProtEin Degrader Optimizer (TORPEDO) platform, to design and optimize small molecule protein degraders that are active against their desired targets by harnessing the body’s natural process for destroying unwanted proteins. Its TORPEDO platform has the capability to design two types of protein degraders and both degrader approaches are reflected in its clinical pipeline. Its product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma and non-Hodgkin lymphoma. Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919.
Contact Information
- Headquarters
- 490 Arsenal Way, Suite 120WATERTOWN, MA, United States 02472
- Phone
- 617-231-0700
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Ronald Cooper
- President, Director
- Andrew Hirsch
- Chief Financial Officer, Treasurer
- Kendra Adams
- Chief People Officer
- Kelly Schick
- Chief Scientific Officer
- Stewart Fisher
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $324.1M |
|---|---|
Revenue (TTM) | $20.0M |
Shares Outstanding | 68.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 3.08 |
EPS | $-2.37 |
Book Value | $4.07 |
P/E Ratio | -2.0x |
Price/Sales (TTM) | 16.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -677.00% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
